PRospective Prostate biOmarker Study (PROPOSe)
PRospective Prostate biOmarker Study (PROPOSe)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Innsbruck, Austria, 6020
- Medizinische Universität Innsbruck
-
-
Oberösterreich
-
Linz, Oberösterreich, Austria, 6020
- Ordensklinikum Linz
-
-
-
-
-
Copenhagen, Denmark, 2200
- Rigshospitalet
-
-
-
-
-
Bad Saarow, Germany, 15526
- HELIOS Klinikum Bad Saarow
-
Bonn, Germany, 53123
- Malteser Krankenhaus Bonn/Rhein-Sieg
-
Braunschweig, Germany, 38126
- Stadtisches Klinikum Braunschweig gGmbH
-
Frankfurt, Germany, 60590
- Universitätsklinikum Frankfurt
-
Hamburg, Germany, 20246
- Martini Klinik am UKE GmbH
-
Herne, Germany, 44625
- Marien-Hospital Herne
-
Stuttgart, Germany, 70176
- Daikonie Klinikum Stuttgart
-
-
NRW
-
Münster, NRW, Germany, 48149
- Universitätsklinikum Münster
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Male patient between 45 and 80 years old.
- tPSA between 2 and 10 ng/ml
- Prostate volume >=35 ml
- Non-suspicious DRE for prostate cancer
- Scheduled for prostate biopsy
- Patient must give written informed consent
Exclusion Criteria:
- Patient not undergoing biopsy of the prostate
- Prior prostate biopsy within the last 12 months
- Transurethral resection of the prostate (TURP) in the last 5 years
- Patients with known acute or chronic prostatitis/cystitis or other known prostate abnormalities
- Patient taking 5-alpha-reductase inhibitor
- Any other prior treatment of the prostate (cryoablation, hifu, ire, radiation therapy, alcohol instillation, etc.)
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
All patients
All
|
During a routine blood draw an additional tube of blood will be taken for the study.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Diagnosis of PCA
Time Frame: 6 months
|
Correlation of the glycoprotein panel algorithm with histological diagnosis of PCa
|
6 months
|
|
Aggressiveness of PCA
Time Frame: 6 months
|
Correlation of the glycoprotein panel algorithm with diagnosis of significant (Gleason Score ≥7) PCa
|
6 months
|
|
Diagnosis of PCA
Time Frame: 12 months
|
Correlation of the glycoprotein panel algorithm with histological diagnosis of PCa
|
12 months
|
|
Aggressiveness of PCA
Time Frame: 12 months
|
Correlation of the glycoprotein panel algorithm with diagnosis of significant (Gleason Score ≥7) PCa
|
12 months
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Glycoprotein panel algorithm
Time Frame: After 12 months
|
Refinement of the glycoprotein panel algorithm
|
After 12 months
|
|
Additional Biomarkers
Time Frame: After 12 months
|
Correlation of additional biomarkers (e. g. olfactomedin 4 (OLFM4), intercellular adhesion molecule 1 (ICAM1), hypoxia up-regulated protein 1(HYOU1) and metallopeptidase inhibitor 1 (TIMP1)) with histological diagnosis of PCa
|
After 12 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Thomas Steuber, Prof. Dr., Martiniklinik am UKE gGmbH
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- PROPOSe_1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.